½ÒÃØÄÉÎ÷æ§Âú¼¶½Å·¨µÄÎå´ó½¹µã¼¼ÇÉ ÄÉÎ÷æ§Âú¼¶½Å·¨..."/> 60+µÄÅ®ÐÔÏëÒª´©³öÓÅÑÅÆøÖÊ £¬°ëÉíȹ¾ø¶ÔÊDz»¿É»òȱµÄʱÉе¥Æ· £¬Ö»ÒªÕÆÎÕÁËÑ¡ÔñºÍ´îÅäµÄ¼¼ÇÉ £¬¾ÍÄܹ»ÇáËÉ´òÔì³öÊôÓÚ×Ô¼ºµÄÓÅÑÅÆø¸Å £¬Õ¹ÏÖ³ö×ÔÐÅÃÔÈ˵Ä÷ÈÁ¦"/>

ÌÚ²©tengbo9885¹ÙÍø

½ÒÃØÄÉÎ÷æ§Âú¼¶½Å·¨µÄÎå´ó½¹µã¼¼ÇÉ ÄÉÎ÷æ§Âú¼¶½Å·¨...

½ÒÃØÄÉÎ÷æ§Âú¼¶½Å·¨µÄÎå´ó½¹µã¼¼ÇÉ ÄÉÎ÷æ§Âú¼¶½Å·¨...

¡¶½ÒÃØÄÉÎ÷æ§Âú¼¶½Å·¨µÄÎå´ó½¹µã¼¼ÇÉ ÄÉÎ÷æ§Âú¼¶½Å·¨...¡·¾çÇé¼ò½é£º60+µÄÅ®ÐÔÏëÒª´©³öÓÅÑÅÆøÖʰëÉíȹ¾ø¶ÔÊDz»¿É»òȱµÄʱÉе¥Æ·Ö»ÒªÕÆÎÕÁËÑ¡ÔñºÍ´îÅäµÄ¼¼ÇɾÍÄܹ»ÇáËÉ´òÔì³öÊôÓÚ×Ô¼ºµÄÓÅÑÅÆø¸ÅÕ¹ÏÖ³ö×ÔÐÅÃÔÈ˵Ä÷ÈÁ¦µ½Á˵ڶþÌìÜÆÔÂÀ´ÕÒÎÊÕÐÄý¿ÉÒªÒ»ÆðÈ¥ÄÇÅÄÂô»áÈ¥¿´¿´ÕÐÄýÒ¡ÁËÒ¡Í·Ëý¿´¹ýÄÇЩÅÄÆ·Ãû²á²¢²»¸ÐÐËȤûÓиúËûÃÇÒ»Æð½ÒÃØÄÉÎ÷æ§Âú¼¶½Å·¨µÄÎå´ó½¹µã¼¼ÇÉ ÄÉÎ÷æ§Âú¼¶½Å·¨...ÁÖÔ¾ÖªµÀµ±ºØ³£ºÍ¿´ÍêÄÇ¿éëÁÏµÄÆ·ÏàºóÒ»¶¨»áÔ½·¢²î±ðÒâ×Ô¼ºµÄ×ö·¨ÖÚÈ˽ÔÔÚ·±»ªÖÐÕÒѰҫÑ۵ύÊâ²»ÖªÔӲݶÑÀïÒ²ÄÜÕÒµ½Æ¯ÁÁµÄÏÊ»¨Ö»ÊÇÐí¶àÈ˲»¿ÏÒâÕÒ°ÕÁ˹ÜÀí¾ü¶Ó²»ÊÇ¿¿µÄËÄÖ«ÅÒª¿¿ÄÔ×ÓµÄ

¡¶½ÒÃØÄÉÎ÷æ§Âú¼¶½Å·¨µÄÎå´ó½¹µã¼¼ÇÉ ÄÉÎ÷æ§Âú¼¶½Å·¨...¡·ÊÓÆµËµÃ÷£ºµÚËÄÈÎÊÇÑÝÔ±ºÎÓêÃÊÒÀ¾ÉÓÐһ˫´óÑÛÔø³öÑݹýÓ°Ï·¡¶Ê®ÔÂΧ³Ç¡·ÍïϧȴûʲôÃûÆøÁܰÍÁö | WHOµÚ5°æÁܰÍ×éÖ¯Ö×Áö·ÖÀà(ÖÐÓ¢±ÈÕÕ×îÈ«×îÊÊÓÃ)Ô­´´2023-07-05 20:58¡¤Ö×Áöר¿ÆÒ½Éú2022ÄêÌìÏÂÎÀÉú×éÖ¯£¨WHO£©Ðû²¼µÚ5°æÔìѪÓëÁܰÍ×éÖ¯Ö×Áö·ÖÀࣨWHO-HAEM5£©The 5th edition of the WHO Calssification of Haematolymphoid TumorsÒ»¡¢ËèϵÔöÖ³ºÍÖ×Áö°üÀ¨¿Ë¡ÐÔÔìѪ¡¢¹ÇËèÔöÖ³ÐÔÖ×Áö£¨ÂýÐÔËèϸ°û°×Ѫ²¡¡¢ÂýÐÔÖÐÐÔÁ£Ï¸°û°×Ѫ²¡µÈ£©¡¢¹ÇËèÔöÉúÒì³£Ö×Áö£¨MDS£©¡¢¼±ÐÔËèϵ°×Ѫ²¡£¨AML£©µÈµÈͨ³£¹éÊôѪҺÄڿƶþ¡¢Ê÷ͻϸ°û/×é֯ϸ°ûÖ×ÁöÊ÷ͻϸ°û/×é֯ϸ°ûÖ×ÁöÔÚаæ·ÖÀàϵͳÖж¨Î»ÓÚËèϵÖ×ÁöÖ®ºóͨ³£ÒÔΪËüÃÇÆðÔ´Ïà½üÆðÔ´ÓÚ³£¼ûµÄËèÏµ×æÏ¸°û£¨±¬·¢µ¥ºËϸ°û/×é֯ϸ°û/Ê÷ͻϸ°ûÆ×ϵ£©µÚËİæ·ÖÀàÖÐ×é֯ϸ°û/Ê÷ͻϸ°ûÖ×ÁöϵÄÂËÅÝÊ÷ͻϸ°ûÈâÁö¡¢ÏËάĸϸ°ûÍø×´Ï¸°ûÖ×ÁöÊÇÓÉÁܰͻùÖÊϸ°û±¬·¢µÄÖ×ÁöµÚÎå°æ·ÖÀཫÆä·Ö³öÀ´¹éµ½ÁܰÍ×éÖ¯¼äÖÊÔ´ÐÔÖ×ÁöÏÂÈý¡¢Bϸ°ûÁܰÍÔöÖ³ÐÔ¼²²¡ºÍÖ×ÁöËÄ¡¢TºÍNKϸ°ûÁܰÍÔöÖ³ÐÔ¼²²¡ºÍÖ×ÁöÎå¡¢ÁܰÍ×éÖ¯¼äÖÊÔ´ÐÔÖ×Áö£¨ÐÂÒýÈë·ÖÀࣩÊôÓÚÁÜϵÖ×Áö£¨ÁܰÍ×éÖ¯Ö×Áö£©±¾ÎÄÖ÷񻃾¼°ÕâÈý²¿·ÖÄÚÈÝÁù¡¢ÒÅ´«Ö×Áö×ÛºÏÕ÷£¨ÐÂÒýÈëÕ½ڣ©ÒÅ´«Ö×Áö×ÛºÏÕ÷°üÀ¨Ò×»¼ËèϵÖ×ÁöºÍÁÜϵÖ×ÁöÏà¹ØµÄ×ÛºÏÕ÷ÒÅ´«ÐÔÖ×Áö×ÛºÏÕ÷£¨ÒÅ´«Ò׸Ð×ÛºÏÕ÷£©ÏµÐÂÒýÈëµÄ·ÖÀà°üÀ¨·¶¿ÉÄáѪÐ飨FanconiѪÐ飩¡¢²¼Â³Ä·×ÛºÏÕ÷£¨Bloom×ÛºÏÕ÷Ãæ²¿ºì°ßÙªÈå×ÛºÏÕ÷£©¡¢¹²¼Ãʧµ÷ëϸѪ¹ÜÀ©ÕÅ×ÛºÏÕ÷£¨AT£©¡¢RAS²¡£¨RAS×ÛºÏÕ÷£©¡¢Nijmegen-Breakage×ÛºÏÕ÷£¨Nijmegen¶ÏÁÑ×ÛºÏÕ÷Nijmegen breakage syndromeNBS£©µÈÒ×»¼ËèϵÖ×ÁöµÄÒÅ´«ÐÔÖ×Áö×ÛºÏÕ÷£ºFanconiѪÐé¡¢RAS²¡µÈATºÍNBSÔòÓëÁÜϵÖ×ÁöÓÈΪÏà¹Ø»®·ÖÓëATMºÍNBNÅßϵͻ±äÏà¹Ø¹ØÓÚµÚ5°æ·ÖÀàµÄ¼¸µãÖ÷Ҫ˵Ã÷£º1¡¢¼²²¡·Ö²ãĿ¼ºÍ½á¹¹×ñÕÕ¹æ¸ñ¼¶±ðµÝÔöµÄ˳ÐòһĿÁËÈ»£ºÖÖ±ðcategory£¨ºÃ±È£º³ÉÊìBϸ°ûÁܰÍÁö£©¡¢¼Ò×å/ÖÖÀàfamily/class£¨ºÃ±È£º´óBϸ°ûÁܰÍÁö£©¡¢ÊµÌå/ÀàÐÍentity/type£¨ºÃ±È£ºÃÖÂþÐÔ´óBϸ°ûÁܰÍÁö¡¢·ÇÌØÖ¸ÐÍ£©ºÍÑÇÐÍsubtype£¨ºÃ±È£ºÃÖÂþÐÔ´ó B ϸ°ûÁܰÍÁö·ÇÌØÖ¸ÐÍÉú·¢ÖÐÐÄBϸ°ûÑù£©2¡¢¼²²¡·ÖÀà×ñÕÕϸ°ûÆ×ϵµÄ˳Ðò£¨Æ×ϵµÄ¹éÊôÒÀ¾ÝÁ÷ʽϸ°ûÊõºÍ/»òÃâÒß×黯µÄÃâÒß±íÐÍÆÊÎö£©ÏÈÊÇǰÌåϸ°ûÖ×ÁöÈ»ºóÊdzÉÊì¶ñÐÔÖ×ÁöÔÚÒ»¸ö¼Ò×å/ÖÖÀࣨfamily/class£©ÖÐʵÌå/ÀàÐÍ£¨entity/type£©Í¨³£°´´Ó¶èÐÔµ½ÇÖÏ®ÐÔ˳ÐòÅÅÁÐ3¡¢ÁܰÍÁöÑù¼²²¡£¨Ò²¾ÍÊÇÓëÁܰÍÁöÁÙ´²ÌØÕ÷ÏàËÆµÄ¼²²¡£©ÒÔ¼°ÐèÒª¼ø±ðµÄ·ÇÖ×Áö¼²²¡Ê×´ÎÄÉÈë·ÖÀàÖÐÓÐÖúÓÚ±ÜÃâÁܰÍÁöÌ«¹ýÕï¶Ï²¢Ìá¸ß¶ÔÁÙ´²²¡Àíѧ²î±ð¼²²¡ÀàÐ͵Äʶ±ð4¡¢ÒýÈëÅßϵÖ×ÁöÒ׸Ð×ÛºÏÕ÷×÷ΪרÃŵĵ¥½ÚÒÔÌåÏÖÆäÈÕÒæÔöÌíµÄÁÙ´²Ö÷ÒªÐÔÕâЩ×ÛºÏÕ÷ͨ³£ÓëËèϵ»òÁÜϵÖ×ÁöÏà¹Ø5¡¢¶ÔÏÈÌìÐÔ£¨Ô­·¢ÐÔ£©ÃâÒßȱÏݺͻñµÃÐÔ£¨¼Ì·¢ÐÔ£©ÃâÒß¼²²¡Ïà¹ØµÄÁܰÍÔöÖ³Ò²ÓÐеķ¢Ã÷¶ÔÕâЩ¸üеÄÄÚÈÝÒ²°üÀ¨ÔÚµÚÎå°æÐ·ÖÀàÖÐ2022 ÄêµÚÎå°æ WHO ÁܰÍ×éÖ¯Ö×Áö·ÖÀࣺÔìѪÓëÁܰÍ×éÖ¯Ö×Áö·ÖÀà £¨WHO-HAEM5£©ÁÜϵÖ×Áö²¿·Ö£ºThe 5th edition of the WHO Calssification of Haematolymphoid Tumors-Lymphoid NeoplasmasÁܰÍ×éÖ¯Ö×Áö£¨ºÏ¼Æ125¸öʵÌå/ÀàÐÍ£©Ò»¡¢Bϸ°ûÁܰÍÔöÖ³ÐÔ¼²²¡ºÍÖ×Áö£¨3ÖÖ±ð79¸öʵÌå/ÀàÐÍ£©1¡¢Bϸ°ûΪÖ÷µÄÖ×ÁöÑù²¡±ä£¨5¸ö£©2¡¢Ç°ÌåBϸ°ûÖ×Áö£¨13¸ö£©3¡¢³ÉÊìBϸ°ûÖ×Áö£¨49¸ö£©4¡¢½¬Ï¸°ûÖ×Áö¼°ÆäËû¾ßÓи±ÂѰ׵ļ²²¡£¨12¸ö£©¶þ¡¢TºÍNKϸ°ûÁܰÍÔöÖ³ÐÔ¼²²¡ºÍÖ×Áö£¨3ÖÖ±ð39¸öʵÌå/ÀàÐÍ£©1¡¢Tϸ°ûΪÖ÷µÄÖ×ÁöÑù²¡±ä£¨3¸ö£©2¡¢Ç°ÌåTϸ°ûÖ×Áö£¨2¸ö£©3¡¢³ÉÊìTºÍNKϸ°ûÖ×Áö£¨34¸ö£©Èý¡¢ÁܰÍ×éÖ¯¼äÖÊÔ´ÐÔÖ×Áö£¨7¸öʵÌå/ÀàÐÍ£©Ï±íÖÐ×ó²à±ß2022ÄêµÚÎå°æWHO-HAEM5·ÖÀࣨÁÜϵ£©ÓÒ²àΪ2017ÄêµÚËİæÐÞ¶©WHO-HAEM4R·ÖÀࣨÁÜϵ£©×¢£ºlymphoproliferative disorder£¨LPD£©Áܰͣ¨×éÖ¯£©ÔöÉúÐÔ¼²²¡Áܰͣ¨×éÖ¯£©ÔöÖ³ÐÔ¼²²¡Bϸ°ûÁܰÍÔöÖ³ÐÔ¼²²¡ºÍÖ×ÁöB-cell lymphoid proliferations and lymphomas£¨79¸öʵÌå/ÀàÐÍ£©Bϸ°ûΪÖ÷Ö×ÁöÑù²¡±ä£¨5¸öʵÌå/ÀàÐÍ£©Tumor-like lesions with B-cell predominanceµÚÎå°æ·ÖÀàµÚËİ棨ÐÞ¶©£©·ÖÀàÓëÁܰÍÁöÏàËÆ£¨ÁܰÍÁöÑù£©·´Ó¦ÐÔ¸»º¬Bϸ°ûµÄÁܰÍϸ°ûÔöÖ³¼²²¡£¨¸»º¬Bϸ°ûµÄ·´Ó¦ÐÔÁܰÍÑùÔöÉú¿ÉÄ£ÄâÁܰÍÁö£©?Reactive B-cell rich lymphoid proliferations that can mimic lymphomaÎÞ£¨µÚËİæÎ´ÁÐÈë²»°üÀ¨ÔÚÄÚÏÂͬ£©IgG4Ïà¹Ø¼²²¡?IgG4-related diseaseÎÞµ¥ÖÐÐÄCastleman²¡?Unicentric Castleman disease£¨UCD£©ÎÞÌØ·¢ÐÔ¶àÖÐÐÄCastleman²¡£¨ÌØ·¢ÐÔMCD£©?Idiopathic multicentric Castleman diseaseÎÞKSHV/HHV8 Ïà¹ØµÄ¶àÖÐÐÄCastleman²¡£¨KSHV/HHV8Ïà¹ØµÄMCD£©?KSHV/HHV8-associated multicenrtric Castleman disease¶àÖÐÐÄCastleman²¡£¨MCD£©¡¾×¢¡¿Bϸ°ûΪÖ÷Ö×ÁöÑù²¡±äϵµÚÎå°æÐÂÒýÈëµÄ·ÖÀà°üÀ¨5¸ö²î±ðµÄ¼²²¡ÊµÌå/ÀàÐÍ£º£¨1£©ÒÔBϸ°ûΪÖ÷µÄ·ÇÖ×ÁöÐÔÁܰÍϸ°ûÔöÉú£¨Éæ¼°ÁÜͶºÏºÍ/»ò½áÍⲿ룩ÓëÁܰÍÁöÏàËÆ£¨ÁܰÍÁöÑù£©Ò²³ÆÎª¸»º¬Bϸ°ûµÄ·´Ó¦ÐÔÁܰÍÑùÔöÉú¿ÉÃþÄâÁܰÍÁö?¸ÃÀ༲²¡°üÀ¨£ºÉú·¢ÖÐÐĵľÙÐÐÐÔת»¯¡¢´«µ¥£¨Ñ¬È¾ÐÔµ¥ºËϸ°ûÔö¶àÖ¢£©¡¢Å®ÐÔÉúÖ³µÀµÄ²ËÃûÌ÷´Ó¦ÐÔÁܰÍ×éÖ¯ÔöÉú/ÁܰÍÁöÑù²¡±ä¡¢ÏµÍ³ÐÔºì°ßÀÇ´¯£¨2£©IgG4Ïà¹Ø¼²²¡?£ºIgG4Ïà¹ØÁÜͶºÏÖ×´ó¾ßÓÐÓëCastleman²¡ÏàÖØµþµÄÌØÕ÷£¨3£©Castleman²¡°üÀ¨ÈýÖÖÀàÐÍ£ºµ¥ÖÐÐÄCastleman²¡?¡¢ÌØ·¢ÐÔ¶àÖÐÐÄCastleman²¡?¡¢KSHV/HHV8 Ïà¹ØµÄ¶àÖÐÐÄCastleman²¡?ËüÃǵÄÁÙ´²ºÍ²¡ÀíÑ§ÌØÕ÷²î±ðǰÌåBϸ°ûÖ×Áö£¨13¸öʵÌå/ÀàÐÍ£©Precursor B-cell neoplasms¼´£ºÔ­Ê¼BÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö£¨BÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁöBÁܰÍĸϸ°û°×Ѫ²¡/ÁܰÍÁöB-cell lymphoblastic leukaemias/lymphomasB-ALL/LBL£©£º£¨1£©BÁܰÍĸϸ°û°×Ѫ²¡/ÁܰÍÁö·ÇÌØÖ¸ÐÍ£¨B-ALL/LBLNOS£©£¨2£©°é½ç˵ÒÅ´«Ñ§Òì³£µÄBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍĸϸ°ûÁܰÍÁö£¨12¸ö£©µÚÎå°æ·ÖÀàµÚËİ棨ÐÞ¶©£©·ÖÀàBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö·ÇÌØÖ¸ÐÍ£¨B-ALL/LBLNOS£©?B-cell lymphoblastic leukaemia/lymphomaNOSÏàͬ°é½ç˵ÒÅ´«Ñ§Òì³£µÄBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍĸϸ°ûÁܰÍÁö£¨12ÖÖ£©BÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö£¨B-ALL/LBL£©°é¸ßÃ÷¶þ±¶Ìå?B-ALL/LBL with high hyperdiploidyBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö£¨B-ALL/LBL£©°é³¬¶þ±¶ÌåBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö£¨B-ALL/LBL£©°éÑǶþ±¶Ì壨µÍ¶þ±¶Ì壩?B-ALL/LBL with hypodiploidyÏàͬBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö£¨B-ALL/LBL£©°éiAMP21?B-ALL/LBL with iAMP21ÏàͬBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö£¨B-ALL/LBL£©°é BCR::ABL1 ÈÚºÏ?B-ALL/LBL with BCR::ABL1 fusionBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö£¨B-ALL/LBL£©°ét(9;22)(q34;q11.2); BCR-ABL1ÈÚºÏBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö£¨B-ALL/LBL£©°é BCR::ABL1 ÑùÌØÕ÷?B-ALL/LBL with BCR::ABL1-like featuresBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö£¨B-ALL/LBL£©, °éBCR-ABL1 ÑùBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö£¨B-ALL/LBL£©°é KMT2A ÖØÅÅ?B-ALL/LBL with KMT2A rearrangementBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö£¨B-ALL/LBL£©°é t(v;11q23.3); KMT2AÖØÅÅBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö£¨B-ALL/LBL£©°é ETV6::RUNX1 ÈÚºÏ?B-ALL/LBL with ETV6::RUNX1 fusionBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö£¨B-ALL/LBL£©°é t(12;21)(p13.2;q22.1); ETV6-RUNX1ÈÚºÏBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö£¨B-ALL/LBL£©°é ETV6::RUNX1ÑùÌØÕ÷?B-ALL/LBL with ETV6::RUNX1-like featuresÎÞBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö£¨B-ALL/LBL£©°é TCF3::PBX1 ÈÚºÏ?B-ALL/LBL with TCF3::PBX1 fusionBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö£¨B-ALL/LBL£©°é t(1;19)(q23;p13.3); TCF3-PBX1ÈÚºÏBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö£¨B-ALL/LBL£©°é IGH::IL3 ÈÚºÏ?B-ALL/LBL with IGH::IL3 fusionBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö£¨B-ALL/LBL£©°é t(5;14)(q31.1;q32.1); IGH/IL3ÈÚºÏBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö£¨B-ALL/LBL£©°é TCF3::HLF ÈÚºÏ?B-ALL/LBL with TCF3::HLF fusionÎÞBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö£¨B-ALL/LBL£©°éÆäËûÌØ¶¨ÒÅ´«Ñ§Òì³£?B-ALL/LBL with other defined genetic abnormalitiesÏàͬ¡¾×¢¡¿B-ALL/LBL·¢²¡»úÖÆÔÚ´ó´ó¶¼ÇéÐÎϱ£´æÒÑÖªµÄÇý¶¯ÒòËØ°üÀ¨iAMP21¡¢BCR::ABL1 Èںϡ¢ KMT2A ÖØÅÅ¡¢ETV6::RUNX1 Èںϡ¢TCF3::PBX1 Èںϡ¢ IGH::IL3 Èںϡ¢TCF3::HLF ÈںϵÈƾ֤ȾɫÌåÊýĿת±ä£¨³¬¶þ±¶Ìå¡¢ÑǶþ±¶ÌåµÈ£©¡¢È¾É«ÌåÖØÅÅ»ò±£´æÆäËûÒÅ´«Çý¶¯ÒòËØ¶ø¹éΪ²î±ðµÄÑÇÐÍ?-?ƾ֤ÈËÀà»ùÒò×é×éÖ¯»ùÒòÃüÃûίԱ»á½¨Òé½ÓÄÉ˫ðºÅ£¨::£©±ê¼ÇÈںϻùÒòÐÂÃû³Æ³ý´ËÖ®Íâ¼´±ã¾­ÓÉÖÜÈ«¼ì²âÒ²ÈÔÈ»ÎÞ·¨·ÖÀàµÄÒ»À༲²¡Ôò¹éΪBÁܰÍϸ°û°×Ѫ²¡/ÁܰÍĸϸ°ûÁܰÍÁö·ÇÌØÖ¸ÐÍ£¨B-ALL/LBLNOS£©?³ÉÊìBϸ°ûÖ×Áö£¨12¸ö¼Ò×å/ÖÖÀà49¸öʵÌå/ÀàÐÍ£©Mature B-cell neoplasms£¨1£©Ö×ÁöǰÆÚºÍÖ×ÁöÐÔСÁܰÍϸ°ûÔöÖ³£¨2¸ö£©£¨2£©Æ¢Bϸ°ûÁܰÍÁöºÍ°×Ѫ²¡£¨4¸ö£©£¨3£©Áܰͽ¬Ï¸°ûÁܰÍÁö£¨1¸ö£©£¨4£©±ßÑØÇøÁܰÍÁö£¨4¸ö£©£¨5£©ÂËÅÝÐÔÁܰÍÁö£¨4¸ö£©£¨6£©Æ¤·ôÂËÅÝÖÐÐÄÁܰÍÁö£¨1¸ö£©£¨7£©Ì×ϸ°ûÁܰÍÁö£¨3¸ö£©£¨8£©¶èÐÔBϸ°ûÁܰÍÁöµÄת»¯£¨1¸ö£©£¨9£©´óBϸ°ûÁܰÍÁö£¨18¸ö£©£¨10£©²®»ùÌØÁܰÍÁö£¨1¸ö£©£¨11£©KSHV/HHV8Ïà¹ØBϸ°ûÁܰÍÔöÖ³ÐÔ¼²²¡ºÍÁܰÍÁö£¨3¸ö£©£¨12£©ÓëÃâÒßȱÏݺÍʧµ÷Ïà¹ØµÄÁܰÍÔöÖ³ºÍÁܰÍÁö£¨5¸ö£©£¨13£©»ôÆæ½ðÁܰÍÁö£¨2¸ö£©µÚÎå°æ·ÖÀàµÚËİ棨ÐÞ¶©£©·ÖÀàÖ×ÁöǰÆÚºÍÖ×ÁöÐÔСÁܰÍϸ°ûÔöÖ³Pre-neoplastic and neoplastic small lymphocytic proliferationsµ¥¿Ë¡ B ÁܰÍϸ°ûÔö¶àÖ¢£¨MBL£©?Monoclonal B-cell lymphocytosisÏàͬÂýÐÔÁܰÍϸ°û°×Ѫ²¡/СÁܰÍϸ°ûÁܰÍÁö£¨CLL/SLL£©?Chronic lymphocytic leukaemia/small lymphocytic lymphomaÏàͬB-PLL²¡Ãû±»É¾³ý£¨²»ÔÙÊÓΪһ¸ö¼²²¡ÀàÐÍ£©Bϸ°ûÓ×ÁܰÍϸ°û°×Ѫ²¡£¨B-PLL£©B-prolymphocytic leukemiaÆ¢Bϸ°ûÁܰÍÁöºÍ°×Ѫ²¡Splenic B-cell lymphomas and leukaemiasëϸ°û°×Ѫ²¡£¨HCL£©?Hairy cell leukaemiaÏàͬƢ±ßÑØÇøÁܰÍÁö£¨SMZL£©?Splenic marginal zone lymphomaÏàͬƢÃÖÂþÐÔºìËèСBϸ°ûÁܰÍÁö£¨SDRPL£©?Splenic diffuse red pulp small B-cell lymphomaÏàͬƢBϸ°ûÁܰÍÁö/°×Ѫ²¡°éÏÔÖøºËÈÊ£¨SBLPN£©?Splenic B-cell lymphoma/leukaemia with prominent nucleoliδ°üÀ¨ÔÚÄÚÎ޴˲¡Ãû£¨µÚËİ没ÃûÊöÓïΪ£ºÃ«Ï¸°û°×Ѫ²¡±äÒìÐͺÍCD5ÒõÐÔBϸ°ûÓ×ÁܰÍϸ°û°×Ѫ²¡£©Áܰͽ¬Ï¸°ûÁܰÍÁöLymphoplasmacytic lymphomaÁܰͽ¬Ï¸°ûÁܰÍÁö£¨LPL£©?Lymphoplasmacytic lymphomaÏàͬ¡¾×¢¡¿°üÀ¨Á½ÖÖÑÇÐÍ£ºIgM-LPL/WM£¨×î³£¼ûÔ¼Õ¼95%£©£ºIgM-LPL/Waldenstrom¾ÞÇòÂѰ×Ѫ²¡£¨WM»ªÊϾÞÇòÂѰ×Ѫ֢£©£»·ÇWMÐÍLPL£¨Ô¼Õ¼5%£©±ßÑØÇøÁܰÍÁöMarginal zone lymphomaճĤÏà¹ØÁܰÍ×éÖ¯½áÍâ±ßÑØÇøÁܰÍÁö£©£¨MALT£©?Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissueÏàͬԭ·¢ÐÔÆ¤·ô±ßÑØÇøÁܰÍÁö£¨PCMZL£©?Primary cutaneous marginal zone lymphomaδµ¥¶ÀÁгö£¨¹éÈëճĤÏà¹ØÁܰÍ×éÖ¯½áÍâ±ßÑØÇøÁܰÍÁö£©ÁÜͶºÏ±ßÑØÇøÁܰÍÁö£¨NMZL£©?Nodal marginal zone lymphomaÏàͬ¶ùͯ(ÁÜͶºÏ)±ßÑØÇøÁܰÍÁö£¨pNMZL£©?Paediatric (nodal) marginal zone lymphomaÏàͬ¡¾×¢¡¿ÆÊ½â²¿Î»²î±ðϸ°ûÒÅ´«Ñ§ºÍ»ùÒòÍ»±äÆ×²î±ð£¨1£©ÁÜͶºÏ±ßÑØÇøÁܰÍÁö£¨NMZL£©ºÍ½áÍâ±ßÑØÇøÁܰÍÁö£¨EMZL£©»ùÒòÍ»±äÆ×²î±ð£¨2£©½áÍâMZL£¨EMZL£©³£¼ûµÄ°üÀ¨Î¸¡¢·Î¡¢ÑÛÁ¥ÊôÆ÷¡¢ÍÙÒºÏÙ¡¢¼××´ÏÙ¡¢Æ¤·ôµÈ²¿Î»µÄMZL²î±ðµÄ½áÍâMZLÖ®¼ä±£´æÏÔÖøµÄÒÅ´«Ñ§²î±ð£¨3£©Æ¤·ôMZL¾ßÓÐÆæÒìµÄÁÙ´²²¡ÀíÌØÕ÷Çø±ðÓÚÆäËû½áÍâMZL£¨EMZL£©¶øµ¥ÁÐ×÷Ϊ×ÔÁ¦µÄ¼²²¡ÊµÌåÀàÐÍ£¨PCMZL£©£¨4£©¶ùͯÁÜͶºÏ±ßÑØÇøÁܰÍÁö£¨pNMZL£©ÊÇ´ÓNMZLϵÄÒ»¸öÑÇÐÍÉý¼¶³ÉΪһ¸ö×ÔÁ¦µÄ¼²²¡ÊµÌåÀàÐÍÂËÅÝÐÔÁܰÍÁöFollicular lymphomaԭλÂËÅÝÐÔBϸ°ûÖ×Áö£¨ISFN£©?In situ follicular B-cell neoplasmԭλÂËÅÝÐÔÖ×Áö£¨Ô­Î»ÂËÅÝÐÔÁö±ä£©ÂËÅÝÐÔÁܰÍÁö£¨FL£©?Follicular lymphomaÏàͬ¶ùͯÐÍÂËÅÝÐÔÁܰÍÁö?Paediatric-type follicular lymphomaÏàͬʮ¶þÖ¸³¦ÐÍÂËÅÝÐÔÁܰÍÁö?Duodenal-type follicular lymphomaÏàͬƤ·ôÂËÅÝÖÐÐÄÁܰÍÁöCutaneous follicle centre lymphomaÔ­·¢ÐÔÆ¤·ôÂËÅÝÖÐÐÄÁܰÍÁö?Primary cutaneous follicle centre lymphomaÏàͬÌ×ϸ°ûÁܰÍÁöMantle cell lymphomaԭλÌ×ϸ°ûÖ×Áö£¨ISMCN£©?In situ mantle cell neoplasmԭλÌ×ϸ°ûÁö±äÌ×ϸ°ûÁܰÍÁö£¨MCL£©?Mantle cell lymphomaÏàͬ°×Ѫ²¡ÐÔ·ÇÁÜͶºÏÐÍÌ×ϸ°ûÁܰÍÁö£¨Leukemic non-nodal mantle cell lymphoma·ÇÁÜͶºÏMCLnnMCL£©?Ïàͬ¡¾×¢¡¿·ÇÁÜͶºÏMCL£¨nnMCL£©ÓëMCLÏà±È´ó¶àûÓÐÖ¢×´ÆäÔ¤ºóÏà¶Ô¸üºÃÖ÷ÒªÊÇѪҺ¡¢¹ÇËèºÍÆ¢ÔàÊÜÀÛºÜÉÙ»òÕßûÓÐÁÜͶºÏÖ×´ó¶èÐÔBϸ°ûÁܰÍÁöת»¯Transformations of indolent B-cell lymphoma¶èÐÔBϸ°ûÁܰÍÁöת»¯?Transformations of indolent B-cell lymphomaÎÞ¡¾×¢¡¿Ê״ΰѶèÐÔBϸ°ûÁܰÍÁöµÄ¸ß¼¶±ðת»¯×÷Ϊһ¸ö×ÔÁ¦²¿·Öµ¥ÁдóBϸ°ûÁܰÍÁöLarge B-cell lymphomas(LBCL)ÃÖÂþ´óBϸ°ûÁܰÍÁö·ÇÌØÖ¸ÐÍ£¨NOS£©?Diffuse large B-cell lymphoma(DLBCL),NOSÏàͬ¸»º¬Tϸ°û/×é֯ϸ°ûµÄ´óBϸ°ûÁܰÍÁö?T-cell/histiocyte-rich large B-cell lymphomaÏàͬÃÖÂþ´óBϸ°ûÁܰÍÁö/¸ß¼¶±ðBϸ°ûÁܰÍÁö°é MYC ºÍ BCL2 ÖØÅÅ?DLBCL/HGBL with MYC and BCL2 rearrangements¸ß¼¶±ðBϸ°ûÁܰÍÁö°é MYC ºÍ BCL2 ºÍ/»ò BCL6 ÖØÅÅALKÑôÐÔ´óBϸ°ûÁܰÍÁö?ALK-positive large B-cell lymphomaÏàͬ´óBϸ°ûÁܰÍÁö°é IRF4 ÖØÅÅ?Lagre B-cell lymphoma with IRF4 rearrangementÏàͬ¸ß¼¶±ðBϸ°ûÁܰÍÁö°é 11q Òì³£?HGBL with 11q aberrationsBurkittÑùÁܰÍÁö°é 11q Òì³£ÁܰÍÁöÑùÈâÑ¿Öײ¡?Lymphomatoid granulomatosisÏàͬEBVÑôÐÔÃÖÂþ´óBϸ°ûÁܰÍÁö?EBV-positive diffuse large B-cell lymphomaEBVÑôÐÔÃÖÂþ´óBϸ°ûÁܰÍÁö·ÇÌØÖ¸ÐÍ£¨NOS£©ÃÖÂþ´óBϸ°ûÁܰÍÁö°éÂýÐÔÑ×Ö¢£¨ÓëÂýÐÔÑ×Ö¢Ïà¹ØµÄÃÖÂþ´óBϸ°ûÁܰÍÁö£©?Diffuse large B-cell lymphoma associated with chronic inflammationÏàͬÏËάÂѰף¨ÏËÎ¬ËØ£©Ïà¹Ø´óBϸ°ûÁܰÍÁö?Fibrin-associated large B-cell lymphoma£¨µÚËİæÊÇÓëÂýÐÔÑ×Ö¢Ïà¹ØµÄÃÖÂþ´óBϸ°ûÁܰÍÁöµÄÒ»¸öÑÇÐÍ£©ÌåÒº¹ýÔØÏà¹Ø´óBϸ°ûÁܰÍÁö?Fluid overload-associated large B-cell lymphomaÎÞ½¬Ä¸Ï¸°ûÁܰÍÁö?Plasmablastic lymphomaÏàͬԭ·¢ÐÔÃâÒß¿íÃⲿλ£¨ÌØÈ¨²¿Î»£©´óBϸ°ûÁܰÍÁö?Primary large B-cell lymphoma of immune-privileged sites£¨µÚËİæÎ´µ¥¶À·ÖÐͰüÀ¨µÚ4°æÖеÄÔ­·¢ÖÐÊàÉñ¾­ÏµÍ³Ô­·¢²£Á§Ìå¡¢ÊÓÍøÄ¤¡¢ØºÍèµÈ²¿Î»µÄÃÖÂþ´óBϸ°ûÁܰÍÁö£©Ô­·¢Æ¤·ôÃÖÂþ´óBϸ°ûÁܰÍÁöÍÈÐÍ?Primary cutaneous diffuse large B-cell lymphoma,leg typeÏàͬѪ¹ÜÄÚ´óBϸ°ûÁܰÍÁö?Intravascular large B-cell lymphomaÏàͬԭ·¢×ݸô´óBϸ°ûÁܰÍÁö?Primary mediastinal large B-cell lymphomaÏàͬ×ݸô»ÒÇøÁܰÍÁö£¨MGZL£©?Mediastinal grey zone lymphomaBϸ°ûÁܰÍÁöÎÞ·¨·ÖÀàÌØÕ÷½éÓÚDLBCLºÍ¾­µä»ôÆæ½ðÁܰÍÁöÖ®¼ä¸ß¼¶±ðBϸ°ûÁܰÍÁö·ÇÌØÖ¸ÐÍ?High-grade B-cell lymphoma(HGBL),NOSÏàͬ¡¾×¢¡¿´óBϸ°ûÁܰÍÁö°üÀ¨DLBCL·ÇÌØÖ¸ÐÍºÍÆäËû17¸öÌØ¶¨´óBϸ°ûÁܰÍÁö£¨1£©DLBCLNOS?ÊÇ×î³£¼ûµÄÀàÐÍÊÇÒ»×éÒìÖÊÐÔµÄÁܰÍÁöÆäÐÎ̬¡¢±íÐ͵Ⱦù²»Öª×ãijÖÖÌØ¶¨´óBϸ°ûÁܰÍÁöµÄÕï¶Ï±ê×¼µÚËİæ½ç˵µÄÁ½ÖÖÖ÷ÒªÑÇÐÍÈÔÊÊÓüÌÐøÇø·ÖGCB/ABC£¨GCB/·ÇGCB£©ÑÇÐÍ£¨2£©ÌåÒº¹ýÔØÏà¹Ø´óBϸ°ûÁܰÍÁö?Ò²ÊÇÐÂÒýÈëµÄÀàÐÍÖ÷ÒªÌåÏÖΪÌåÇ»ÊÜÀÛ×î³£¼ûÊÇÐØÄ¤Ç»ÊÜÀÛ³£Óе¼ÖÂÒºÌå¹ýÔØµÄ»ù´¡¼²²¡£¨ÂýÐÔÐÄË¥¡¢ÉöË¥½ß¡¢¸ÎË¥½ß/¸ÎÓ²»¯µÈ£©¶à¼ûÓÚÍíÄêÈËÔ¤ºóÏà¶Ô½ÏºÃÒª×¢ÖØËüÓëÔ­·¢ÐÔÉøÍ¸ÐÔÁܰÍÁö£¨PEL£©»ùÒò±í´ïÆ×ºÍÔ¤ºó¾ù²î±ðPELÔ¤ºó¸ü²îPELÏÖÔÚ¹éÈëKSHV/HHV8Ïà¹ØBϸ°ûÁܰÍÔöÖ³ÐÔ¼²²¡ºÍÁܰÍÁöÕâÒ»¼Ò×å/ÖÖÀàÖУ¨3£©ÃâÒß¿íÃⲿλµÄÔ­·¢´óBϸ°ûÁܰÍÁö?Ҳаæ·ÖÀàÒýÈëµÄÒ»¸öеÄ×ܳÆÊDZ¬·¢ÓÚÃâÒß¹¦Ð§Õý·²ÈËȺµÄÒ»×éÔ­·¢ÇÖÏ®ÐÔBϸ°ûÁܰÍÁöÔ­·¢²¿Î»°üÀ¨ÖÐÊàÉñ¾­ÏµÍ³¡¢²£Á§ÌåÊÓÍøÄ¤¡¢ØºÍ裺ԭ·¢ÐÔÖÐÊàÉñ¾­ÏµÍ³DLBCL¡¢Ô­·¢ÐÔØºÍèLBCL¡¢Ô­·¢ÐÔ²£Á§ÌåÊÓÍøÄ¤LBCLδÀ´¿ÉÄÜ»¹»áÀ©³ä£¨ºÃ±ÈÈéÏÙ¡¢Æ¤·ôµÈ£©£¨4£©×ݸô»ÒÇøÁܰÍÁö£¨MGZL£©?¾ßÓÐÔ­·¢×ݸôBϸ°ûÁܰÍÁö£¨PMBL£©ºÍ¾­µä·¶»ôÆæ½ðÁܰÍÁö£¨cHL£©µÄÖØµþÌØÕ÷½ö±¬·¢ÓÚ×ݸôÊôÓÚ¼òµ¥ÉúÎïÑ§ÌØÕ÷µÄ¼²²¡ÊµÌåBurkittÁܰÍÁöBurkitt lymphomaBurkittÁܰÍÁö£¨²®»ùÌØÁܰÍÁö£©?Burkitt lymphoma(BL)Ïàͬ¡¾×¢¡¿²®»ùÌØÁܰÍÁö¼ÈÍùƾ֤ʢÐв¡Ñ§Åä¾°ºÍµØÀíλÖ÷ÖΪÈýÖÖÊ¢Ðв¡Ñ§ÑÇÐÍ£ºµØ·½ÐÔBL¡¢·ÇµØ·½ÐÔ/É¢·¢ÐÔBL¡¢ÃâÒßȱÏÝÏà¹ØBL˼Á¿µ½EBVѬȾÔÚÔçÆÚ·¢²¡»úÖÆÖÐÆðÖ÷Òª×÷ÓûùÓÚ·Ö×ÓÌØÕ÷Çø·ÖΪÁ½ÖÖÑÇÐÍÈ¡´úÊ¢Ðв¡Ñ§ÑÇÐͼ´£ºEBVÑôÐÔBLºÍEBVÒõÐÔBLKSHV/HHV8Ïà¹ØBϸ°ûÁܰÍÔöÖ³ÐÔ¼²²¡ºÍÁܰÍÁöKSHV/HHV8-associated B-cell lymphoid proliferations and lymphomasÔ­·¢ÐÔÉøÍ¸ÐÔÁܰÍÁö£¨PEL£©?Primary effusion lymphomaÏàͬKSHV/HHV8ÑôÐÔÃÖÂþ´óBϸ°ûÁܰÍÁö?KSHV/HHV8-positive diffuse large B-cell lymphomaHHV8ÑôÐÔÃÖÂþ´óBϸ°ûÁܰÍÁö·ÇÌØÖ¸ÐÍKSHV/HHV8ÑôÐÔÊÈÉú·¢ÖÐÐÄÁܰÍÔöÖ³ÐÔ¼²²¡?HSHV/HHV8-positive germinotropic lymphoproliferative disorderHHV8ÑôÐÔÊÈÉú·¢ÖÐÐÄÁܰÍÔöÖ³ÐÔ¼²²¡¡¾×¢¡¿KSHV/HHV8£¨¿¨²¨Î÷ÈâÁöðåÕ¶¾/ÈËÀàðåÕ¶¾8ÐÍ£©Ñ¬È¾Ïà¹ØµÄÁܰÍÔöÖ³ÐÔ¼²²¡°üÀ¨£ºKSHV/HHV8Ïà¹ØµÄ¶àÖÐÐÄCastleman²¡£¨KSHV/HHV8-MCD¹éµ½Bϸ°ûΪÖ÷µÄÖ×ÁöÑù²¡±äÖÖ±ðÏ£©¡¢Ô­·¢ÐÔÉøÍ¸ÐÔÁܰÍÁö?£¨Primary effusion lymphomaPEL£©¡¢Ç»ÍâPEL£¨EC-PEL£©¡¢KSHV/HHV8ÑôÐÔÃÖÂþ´óBϸ°ûÁܰÍÁö?£¨KSHV/HHV8-DLBCL£©¡¢KSHV/HHV8ÑôÐÔÊÈÉú·¢ÖÐÐÄÁܰÍÔöÖ³ÐÔ¼²²¡?£¨KSHV/HHV8-GLPD£©ÓëÃâÒßȱÏݺÍʧµ÷Ïà¹ØµÄÁܰÍÔöÖ³ºÍÁܰÍÁöLymphoid proliferations and lymphomas associated with immune deficiency and dysregulationÃâÒßȱÏÝÏà¹ØÐÔÈ÷°Í×éÖ¯ÔöÉúÐÔ¼²²¡ÃâÒßȱÏÝ/ʧµ÷£¨IDD£©ÒýÆðµÄÌ«¹ýÔöÉú?Hyperplasias arising in immune deficiency/dysregulationδÁÐÈëµÚËİ治°üÀ¨ÔÚÄÚµÚËİæ°üÀ¨·Ç£¨×éÖ¯£©ÆÆËðÐÔÒÆÖ²ºóÁܰÍÔöÖ³ÐÔ¼²²¡£¨·ÇÆÆËðÐÔPTLD£©µÈÃâÒßȱÏÝ/ʧµ÷ÒýÆðµÄ¶àÐÎÐÔÁܰÍÔöÖ³£¨¶àÐÎÐÔÁܰÍ×éÖ¯ÔöÖ³ÐÔ¼²²¡£©?Polymorphic lymphoproliferative disorders arising in immune deficiency/dysregulationδÁÐÈ루µÚËİ治°üÀ¨ÔÚÄÚ°üÀ¨¶àÐÎÐÔÒÆÖ²ºóÁܰÍ×éÖ¯ÔöÖ³ÐÔ¼²²¡£¨¶àÐÎÐÔPTLD£©¡¢ÆäËûÒ½Ô´ÐÔÃâÒßȱÏÝÏà¹ØµÄÁܰÍ×éÖ¯ÔöÉúÐÔ¼²²¡µÈ£©EBVÑôÐÔÆ¤·ôճĤÀ£Ññ?EBV-positive mucocutaneous ulcer(EBVMCU)ÏàͬÃâÒßȱÏÝ/ʧµ÷ÒýÆðµÄÁܰÍÁö?Lymphoma arising in immune deficiency/dysregulationδÁÐÈëµÚËİ治°üÀ¨ÔÚÄÚµÚËİæ°üÀ¨µ¥ÐÎÐÔÒÆÖ²ºóÁܰÍ×éÖ¯ÔöÖ³ÐÔ¼²²¡£¨µ¥ÐÎÐÔPTLD£©¡¢¾­µä·¶»ôÆæ½ðÁܰÍÁöÑùÒÆÖ²ºóÁܰÍ×éÖ¯ÔöÖ³ÐÔ¼²²¡¡¢HIVѬȾÏà¹ØÁܰÍÁöµÈ£©ÃâÒßÏà¹ØÁܰÍÑùÔöÉúºÍÁܰÍÁöµÄÏÈÌìÐÔ¹ýʧ£¨ÏÈÌìÐÔÃâÒßȱÏÝÏà¹ØÁܰÍÔöÖ³ºÍÁܰÍÁöÃâÒß³öÉú¹ýʧÏà¹ØµÄÁܰÍÔöÖ³ºÍÁܰÍÁö£©?Inborn error of immunity-associated lymphoid proliferations and lymphomasÁܰÍÔöÖ³ÐÔ¼²²¡Ïà¹Ø°éÔ­·¢ÃâÒß¼²²¡£¨ÓëÔ­·¢ÐÔÃâÒß¼²²¡/ȱÏÝÏà¹ØµÄÁܰÍÔöÖ³ÐÔ¼²²¡£©¡¾×¢¡¿ÃâÒßȱÏÝ/ʧµ÷ÃâÒßȱÏݲ¡£¨immunodeficiency diseasesIDD£©ÊÇÒ»×éÓÉÓÚÃâÒßϵͳ·¢Óý²»È«»òÔâÊÜËðº¦ËùÖµÄÃâÒß¹¦Ð§È±ÏÝÒýÆðµÄ¼²²¡ÓжþÖÖÀàÐÍ£º¢ÙÔ­·¢ÐÔÃâÒßȱÏݲ¡£¨ÏÈÌìÐÔÃâÒßȱÏݲ¡£©ÓëÒÅ´«ÓйØ¶à±¬·¢ÔÚÓ¤Ó×¶ù¢Ú¼Ì·¢ÐÔÃâÒßȱÏݲ¡£¨»ñµÃÐÔÃâÒßȱÏݲ¡£©¿É±¬·¢ÔÚÈκÎÄêËê¶àÒòÑÏÖØÑ¬È¾ÓÈÆäÊÇÖ±½ÓÇÖÕ¼ÃâÒßϵͳµÄѬȾ¡¢¶ñÐÔÖ×Áö¡¢Ó¦ÓÃÃâÒßÒÖÖÆ¼Á¡¢·ÅÁÆ»¯ÁƵÈÔµ¹ÊÔ­ÓÉÒýÆðÓëÅßϵͻ±äÏà¹ØµÄÔ­·¢ÐÔÃâÒßȱÏݱ»¹ú¼ÊÃâÒßѧ»áÍŽá»áÖØÐÂÃüÃûΪÃâÒß³öÉú¹ýʧ£¨inborn error of immunity,IEI£©£¨¼ÈÍù³ÆÎªÏÈÌìÐÔÃâÒßȱÏÝ£©аæWHO-HAEM5·ÖÀà½ÓÄɸÃÊõÓïÃû³Æ»ôÆæ½ðÁܰÍÁöHodgkin lymphma¾­µä·¶»ôÆæ½ðÁܰÍÁö?Classic Hodgkin lymphma£¨cHL£©Ïàͬ½á½ÚÐÔÁܰÍϸ°ûΪÖ÷ÐÍ»ôÆæ½ðÁܰÍÁö?Nodular lymphocyte predominant Hodgkin lymphma£¨NLPHL£©Ïàͬ¡¾×¢¡¿»ôÆæ½ðÁܰÍÁöÔھɰæÖÐ×÷Ϊ×ÔÁ¦µÄÖÖ±ð£¨category£©Hodgkinϸ°û£¨RSϸ°ûµÄµ¥ºË±äÒìÐÍ£©ºÍReed-Sternbergϸ°û£¨Àï˹ϸ°ûRSϸ°ûÌåÏÖΪ¶àºË¾Þϸ°û£©ÆðÔ´ÓÚÉú·¢ÖÐÐĵÄBϸ°û²¢Ë¼Á¿µ½½ñÊÀµÄÖÎÁÆÄ£Ê½°Ñ»ôÆæ½ðÁܰÍÁöµ¥¶À·Ö³öÀ´µÄÔ¤ºóÒâÒå²»´óÒò´Ëаæ·ÖÀà°Ñ»ôÆæ½ðÁܰÍÁö±»¹éµ½³ÉÊìBϸ°ûÖ×ÁöÖÖ±ð£¨category£©ÏÂ×÷Ϊ³ÉÊìBϸ°ûÖ×ÁöµÄÒ»¸ö¼Ò×å/ÖÖÀࣨfamily/class£©ÁܰÍϸ°ûΪÖ÷ÐÍ»ôÆæ½ðÁܰÍÁö£¨LPHL£©Õ¼»ôÆæ½ðÁܰÍÁö5%-6%´ó²¿·ÖÔڵͱ¶¾µÏ¿ɼûµ½½á½ÚÑù½á¹¹Å侰ΪСÁܰÍϸ°ûȺ¼¯÷缯³Ê½á½ÚÂþÑÜÏàËÆÓÚÂËÅÝÁܰÍÁöÒ²³ÆÎª½á½ÚÐÔÁܰÍϸ°ûΪÖ÷ÐÍHL£¨NLPHL£©½öÓÐÉÙÉÙÊýÕï¶ÏÐÔµÄRSϸ°ûÇÒ³£ÎªÒ»Àà³ÆÎªL£¦HRSϸ°ûÒ²³ÆÎªHLµÄϸ°ûϸ°ûºÍ/»ò×é֯ϸ°ûÑÇÐÍÒ²³ÆÎª±¬Ã×»¨Ï¸°û¿É±¬·¢ÔÚÈκÎÄêËêÖÐλ·¢²¡ÄêËê60ËêÄÐÐÔ¶à¼û³£ÇÖÕ¼ÁÜͶºÏÔ¤ºó½ÏºÃÃâÒß×黯ȾɫCD30£¨-£©±í´ïBϸ°û¿¹Ô­£¨CD20+CD15-£©¿ÉºóÆÚ¸´·¢¿Éת»¯ÎªBϸ°ûNHL¾­µä·¶»ôÆæ½ðÁܰÍÁö£¨CHL£©¾ßÓÐÐÎ̬ѧµä·¶µÄÕï¶ÏÐÔRSϸ°û¼°Æäµ¥ºË±äÒìÐÍ£¨»ôÆæ½ðϸ°û£©Áöϸ°ûÌØÕ÷ÐÔ±í´ïCD30+³£±í´ïCD15+CE20-°üÀ¨ËĸöÑÇÐÍ£º½á½ÚÓ²»¯ÐÍcHL£¨NSCHL£©¡¢¸»ÓÚÁܰÍϸ°ûÐÍcHL£¨LRCHL£©¡¢»ìÏýϸ°ûÐÍcHL£¨MCHL£©¡¢ÁܰÍϸ°ûÏû¼õÐÍcHL£¨LDCHL£©½¬Ï¸°ûÖ×Áö¼°ÆäËû¾ßÓи±ÂѰ׵ļ²²¡£¨12¸öʵÌå/ÀàÐÍ£©Plasma cell neoplasms and other diseases with paraproteinsµÚÎå°æ·ÖÀàµÚËİ棨ÐÞ¶©£©·ÖÀ൥¿Ë¡±ûÖÖÇòÂѰײ¡Monoclonal gammopathiesÀäÄý¼¯Ëز¡£¨CAD£©?Cold agglutinin diseaseÎÞÒâÒåδÃ÷µÄIgMµ¥¿Ë¡±ûÖÖÇòÂѰײ¡?IgM monoclonal gammopathy of undetermined significance£¨IgM MGUS£©ÏàÔÞ³ÉÒåδÃ÷µÄ·ÇIgMµ¥¿Ë¡±ûÖÖÇòÂѰײ¡?Non-IgM MGUSÏàͬ¾ßÓÐÉöÔàÒâÒåµÄµ¥¿Ë¡±ûÖÖÇòÂѰײ¡?Monoclonal gammopathy of renal significance(MGRS)δÁÐ Èëµ¥¿Ë¡ÃâÒßÇòÂѰ׳Á»ýµÄ¼²²¡Diseases with monoclonal immunoglobulin depositionÃâÒßÇòÂѰ×Ïà¹Ø£¨AL£©µí·ÛÑù±äÐÔ?Immunoglobulin-related(AL) amyloidosisÔ­·¢ÐÔ£¨ÇáÁ´£©µí·ÛÑù±äÐÔµ¥¿Ë¡ÃâÒßÇòÂѰ׳Á»ý²¡?Monoclonal immunoglobulin deposition diseaseÇáÁ´ºÍÖØÁ´³Á»ý²¡ÖØÁ´²¡Heavy chain diseases£¨HCD£©¦Ì£¨Mu£©ÖØÁ´²¡?Mu heavy chain diseaseÏàͬ¦Ã£¨Gamma£©ÖØÁ´²¡?Gamma heavy chain diseaseÏàͬ¦Á£¨Alpha£©ÖØÁ´²¡?Alpha heavy chain diseaseÏàͬ½¬Ï¸°ûÖ×ÁöPlasma cell neoplasms½¬Ï¸°ûÁö?PlasmacytomaÏàͬ½¬Ï¸°û¹ÇËèÁö?Plasma cell myeloma/multiple myelomaÏàͬ¸±Ö×Áö×ÛºÏÕ÷Ïà¹ØµÄ½¬Ï¸°ûÖ×Áö?Plasma cell neoplasms with associated paraneoplastic syndromePOEMS ×ÛºÏÕ÷TEMPI ×ÛºÏÕ÷AESOP ×ÛºÏÕ÷£¨adenopathy and extensive skin patch overlying a plasmacytomaÁÜͶºÏÖ×´óºÍÆÕ±éƤ·ô°ß¿é°é½¬Ï¸°ûÁö£©Ïàͬ£¨µ«AESOP ×ÛºÏÕ÷ÒÔǰ²»°üÀ¨ÔÚÄÚ£©TºÍNKϸ°ûÁܰÍÔöÖ³ÐÔ¼²²¡ºÍÖ×ÁöT-cell and NK-cell lymphoid proliferations and lymphomas£¨39¸öʵÌå/ÀàÐÍ£©Tϸ°ûΪÖ÷Ö×ÁöÑù²¡±ä£¨3¸öʵÌå/ÀàÐÍ£©Tumor-like lesions with T-cell predominanceµÚÎå°æ·ÖÀàµÚËİ棨ÐÞ¶©£©·ÖÀà¾Õ³Ø-ÌÙ±¾²¡?Kikuchi-Fujimoto disease(KFD)ÎÞ¶èÐÔ T ÁܰÍĸϸ°ûÐÔÔöÖ³?Indolent T-lymphoblastic proliferation(ITLP)ÎÞ×ÔÉíÃâÒßÐÔÁܰÍÔöÖ³×ÛºÏÕ÷?Autoimmune lymphoproliferative syndrome(ALPS)ÎÞ¡¾×¢¡¿Tϸ°ûΪÖ÷Ö×ÁöÑù²¡±äϵµÚÎå°æÐÂÒýÈëµÄ·ÖÀàǰÌåTϸ°ûÖ×Áö£¨2¸öʵÌå/ÀàÐÍ£©Precursor T-cell neoplasms¼´£ºÔ­Ê¼TÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁö£¨TÁܰÍϸ°û°×Ѫ²¡/ÁܰÍÁöTÁܰÍĸϸ°û°×Ѫ²¡/ÁܰÍÁöT-lymphoblastic leukaemias/lymphomasT-ALL/LBL£©µÚÎå°æ·ÖÀàµÚËİ棨ÐÞ¶©£©·ÖÀàTÁܰÍĸϸ°û°×Ѫ²¡/ÁܰÍÁö·ÇÌØÖ¸ÐÍ?T-lymphoblastic leukaemia/lymphoma,NOS£¨T-ALL/LBLNOS£©TÁܰÍĸϸ°û°×Ѫ²¡/ÁܰÍÁöÔçÆÚTǰÌåÁܰÍĸϸ°û°×Ѫ²¡/ÁܰÍÁö?Early T-precursor ALL/LBL (ETP-ALL/LBL)ÔçÆÚTǰÌåÁܰÍϸ°û°×Ѫ²¡£¨ÒÑɾ³ý£©NKÁܰÍĸϸ°û°×Ѫ²¡/ÁܰÍÁö£¨Ô­Ê¼NKϸ°û°×Ѫ²¡/ÁܰÍÁö£©¡¾×¢¡¿NKÁܰÍĸϸ°û°×Ѫ²¡/ÁܰÍÁöÔÚµÚËİæ·ÖÀàÖÐ×÷ΪÔÝʱ¼²²¡ÀàÐÍÓÉÓÚȱ·¦Ã÷È·µÄ¿É¿¿µÄÕï¶Ï±ê×¼ÒÔ¼°Ïà¹ØµÄÐÎ̬ѧºÍÃâÒß±íÐÍÌØÕ÷µÚÎå°æ·ÖÀàÖÐδµ¥¶ÀÁгö³ÉÊìTϸ°ûºÍNKϸ°ûÖ×Áö£¨9¸ö¼Ò×å/ÖÖÀà34¸öʵÌå/ÀàÐÍ£©Mature T-cell and NK-cell neoplasms£¨1£©³ÉÊìTϸ°ûºÍNKϸ°û°×Ѫ²¡£¨6¸ö£©£»£¨2£©Ô­·¢ÐÔÆ¤·ôTϸ°ûÁܰÍÁö£¨9¸ö£©£»£¨3£©³¦µÀTϸ°ûºÍNKϸ°ûÁܰÍÔöÖ³ºÍÁܰÍÁö£¨5¸ö£©£»£¨4£©¸ÎÆ¢Tϸ°ûÁܰÍÁö£¨1¸ö£©£»£¨5£©¼ä±äÐÔ´óϸ°ûÁܰÍÁö£¨3¸ö£©£»£¨6£©ÁÜͶºÏTÂËÅݸ¨Öúϸ°ûÁܰÍÁö£¨3¸ö£©£»£¨7£©ÆäËûÍâÖÜTϸ°ûÁܰÍÁö£¨1¸ö£©£»£¨8£©EBVÑôÐÔNK/Tϸ°ûÁܰÍÁö£¨2¸ö£©£»£¨9£©¶ùͯEBVÑôÐÔTϸ°ûºÍNKϸ°ûÁܰÍÔöÖ³ºÍÁܰÍÁö£¨4¸ö£©¡¾×¢¡¿³ÉÊìTϸ°ûºÍNKϸ°ûÖ×Áöƾ֤ϸ°ûÆðÔ´/·Ö½â״̬¡¢ÁÙ´²ÌØÕ÷¡¢¼²²¡²¿Î»/λÖá¢Ï¸°ûÐÎ̬ѧµÈÇø·ÖΪ9¸ö¼Ò×å/ÖÖÀ๲34¸ö¼²²¡ÊµÌå/ÀàÐÍ´ó´ó¶¼Tϸ°û¡¢NKϸ°ûÖ×Áö¿É¹éÈë¸÷×ÔÏìÓ¦µÄTϸ°û¡¢NKϸ°ûÆ×ϵµ«Óеļ²²¡ÀàÐͰüÀ¨NKϸ°û¡¢Tϸ°û¡¢»ìÏý»ò²»È·¶¨µÄÖ×Áö±íÐÍTϸ°ûºÍNkϸ°ûÆðÔ´µÄÇø·ÖÄÑÓÚÈ·¶¨»ò²»ÇåÎúÒò´ËµÚÎå°æ·ÖÀàÖÐûÓмòÆÓµØ·ÖΪTϸ°ûÖ×ÁöºÍNKϸ°ûÁ½ÀàºÃ±È³ÉÊìTϸ°ûºÍNKϸ°û°×Ѫ²¡¡¢EBV-ÑôÐÔ½áÐÔTϸ°ûºÍNKϸ°ûÁܰÍÁö¡¢½áÍâNK/Tϸ°ûÁܰÍÁöµÈµÚÎå°æ·ÖÀàµÚËİ棨ÐÞ¶©£©·ÖÀà³ÉÊìTϸ°ûºÍNKϸ°û°×Ѫ²¡Mature T-cell and NK-cell leukaemiasT-Ó×ÁܰÍϸ°û°×Ѫ²¡£¨T-PLL£©?T-prolymphocytic leukaemiaÏàͬT´ó¿ÅÁ£ÁܰÍϸ°û°×Ѫ²¡£¨T-LGLL£©?T-large granular lymphocytic leukaemiaTϸ°û£¨´ó¿ÅÁ££©ÁܰÍϸ°û°×Ѫ²¡NK´ó¿ÅÁ£ÁܰÍϸ°û°×Ѫ²¡£¨NK-LGLL£©?NK-large granular lymphocytic leukaemiaNKϸ°ûÂýÐÔÁܰÍÔöÉúÐÔ¼²²¡³ÉÈË T ϸ°û°×Ѫ²¡/ÁܰÍÁö£¨ATLL£©?Adult T-cell leukaemia/lymphomaÏàͬSezary×ÛºÏÕ÷£¨ÈûÔúÀï×ÛºÏÕ÷SS£©?S¨¦zary syndromeÏàͬÇÖÏ®ÐÔ NK ϸ°û°×Ѫ²¡£¨ANKL£©?Aggressive NK-cell leukaemiaÏàͬԭ·¢ÐÔÆ¤·ôTϸ°ûÁܰÍÁöPrimary cutaneous T-cell lymphomasÔ­·¢ÐÔÆ¤·ô CD4 ÑôÐÔС /ÖÐT ϸ°ûÁܰÍÔöÖ³ÐÔ¼²²¡?Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorderÏàͬԭ·¢ÐÔÆ¤·ôÖ«¶Ë CD8 ÑôÐÔÁܰÍÔöÖ³ÐÔ¼²²¡?Primary cutaneous acral CD8-positive lymphoproliferative disorderÔ­·¢ÐÔÆ¤·ôÖ«¶Ë CD8 ÑôÐÔ T ϸ°ûÁܰÍÁöÞ¦ÑùÈâÑ¿Ö×?Mycosis fungoides(MF)Ïàͬԭ·¢ÐÔÆ¤·ôCD30ÑôÐÔTϸ°ûÁܰÍÔöÖ³ÐÔ¼²²¡£ºÁܰÍÁöÑùÇðÕ?Primary cutaneous CD30-positive T-cell LPD:Lymphomatoid papulosisÏàͬԭ·¢ÐÔÆ¤·ôCD30ÑôÐÔTϸ°ûÁܰÍÔöÖ³ÐÔ¼²²¡£ºÔ­·¢ÐÔÆ¤·ô¼ä±äÐÔ´óϸ°ûÁܰÍÁö?Primary cutaneous CD30-positive T-cell LPD:Primary cutaneous ALCLÏàͬƤÏÂ֬ĤÑ×ÑùTϸ°ûÁܰÍÁö?Subcutaneous panniculitis-like T-cell lymphomaÏàͬԭ·¢ÐÔÆ¤·ô ¦Ã/¦Ä T ϸ°ûÁܰÍÁö?Primary cutaneous gamma/delta T-cell lymphomaÏàͬԭ·¢ÐÔÆ¤·ôCD8ÑôÐÔÇÖÏ®ÐÔÊÈ±íÆ¤Ï¸°û¶¾ÐÔTϸ°ûÁܰÍÁö?Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphomaÏàͬԭ·¢ÐÔÆ¤·ôÍâÖÜTϸ°ûÁܰÍÁö·ÇÌØÖ¸ÐÍ£¨NOS£©?Primary cutaneous peripheral T-cell LPD,NOSÎÞ¡¾×¢¡¿Ô­·¢ÐÔÆ¤·ôTϸ°ûÁܰÍÁö£¨CTCL£©ÊÇаæ·ÖÀàÖгÉÊìT/NKϸ°ûÖ×ÁöÖÖ±ðϵÄÒ»¸öרÃŵļÒ×å/ÖÖÀà°üÀ¨9¸ö¼²²¡ÊµÌå/ÀàÐͳ¦µÀTϸ°ûºÍNKϸ°ûÁܰÍÔöÖ³ºÍÁܰÍÁöIntestinal T-cell and NK-cell Lymphoid proliferations and lymphomas賦µÀ¶èÐÔTϸ°ûÁܰÍÁö?Indolent T-cell lymphoma of the gastrointestinal tract賦µÀ¶èÐÔTϸ°ûÁܰÍÔöÖ³ÐÔ¼²²¡Î¸³¦µÀ¶èÐÔ NK ϸ°ûÁܰÍÔöÖ³ÐÔ¼²²¡?Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tractÎÞ³¦²¡Ïà¹ØTϸ°ûÁܰÍÁö?Enteropathy-associated T-cell lymphomaÏàͬµ¥ÐÎÐÔÊÈÉÏÆ¤ÐÔ³¦µÀ T ϸ°ûÁܰÍÁö?Monomorhpic epitheliotropic intestinal T-cell lymphomaÏàͬ³¦ µÀT ϸ°ûÁܰÍÁö·ÇÌØÖ¸ÐÍ£¨NOS£©?Intestinal T-cell lymphoma ,NOSÏàͬ¡¾×¢¡¿Î¸³¦µÀ£¨GI£©¶èÐÔTϸ°ûÁܰÍÔöÖ³ÐÔ¼²²¡ÐÂÃüÃûΪ賦µÀ¶èÐÔTϸ°ûÁܰÍÁöÃüÃû´ÓÁܰÍÔöÖ³ÐÔ¼²²¡µ½ÁܰÍÁöµÄת±äÊÇ»ùÓÚÆä¸ß±¬·¢Âʺͼ²²¡µÄ²¥É¢ÐÔµ«ÁÙ´²Àú³ÌÈÔÈ»Âþ³¤ÒÔÊÇÈÔ±£´æ¶èÐÔÕâÒ»ÏÞÖÆ´Ê賦µÀ¶èÐÔNKϸ°ûÁܰÍÔöÖ³ÐÔ¼²²¡£¨iNKLPD,indolent NK-cell lymphoproliferative disorder£©ÊÇÐÂÔöÀàÐͼÈÍùÒÔΪÊÇÒ»ÖÖ·´Ó¦ÐÔÀú³Ì¶ø³ÆÎªÁܰÍÁöÑùθ²¡»òNKϸ°û³¦²¡µ«×î½üµÄ·¢Ã÷Ö§³ÖËüµÄÖ×ÁöÐÔÌØÕ÷Òò´ËÐÂÒýÈë×÷Ϊһ¸ö×ÔÁ¦µÄ¼²²¡ÊµÌå/ÀàÐÍ¸ÎÆ¢Tϸ°ûÁܰÍÁöHepatosplenic T-cell lymphoma¸ÎÆ¢Tϸ°ûÁܰÍÁö£¨HSTCL£©?Hepatosplenic T-cell lymphomaÏàͬ¼ä±äÐÔ´óϸ°ûÁܰÍÁöAnaplastic large cell lymphomaALK-ÑôÐÔ¼ä±äÐÔ´óϸ°ûÁܰÍÁö?ALK-positive anaplastic large cell lymphoma£¨ALK+ALCL£©¼ä±äÐÔ´óϸ°ûÁܰÍÁö, ALK-ÑôÐÔALK-ÒõÐÔ¼ä±äÐÔ´óϸ°ûÁܰÍÁö?ALK-negative anaplastic large cell lymphoma£¨ALK-ALCL£©¼ä±äÐÔ´óϸ°ûÁܰÍÁö, ALK-ÒõÐÔÈé·¿Ö²ÈëÎïÏà¹Ø¼ä±äÐÔ´óϸ°ûÁܰÍÁö?Breast implant-associated anaplastic large cell lymphoma£¨BIA-ALCL£©Ïàͬ¡¾×¢¡¿¼äÖʱäÐÔ´óϸ°ûÁܰÍÁö£¨ALCL£©¼Ò×å°üÀ¨3¸ö¼²²¡ÊµÌå/ÀàÐÍ£ºALK+ALCL¡¢ALK-ALCL¡¢BIA-ALCL¾ùΪ³ÉÊìTϸ°ûÁܰÍÁöCD30Ç¿±í´ïͨ³£²»±í´ïTϵ±ê¼ÇÎïÔ­·¢ÐÔÆ¤·ôALCLûÓйéÔڸüÒ×å϶øÊǹéÀൽÁíÒ»¼Ò×åÔ­·¢ÐÔÆ¤·ôTϸ°ûÁܰÍÔöÖ³ºÍÁܰÍÁöÏÂÆäÓëÈ«ÉíÐÔALK-ALCLÏà±ÈÔ¤ºó¸ü¼ÑÈé·¿Ö²ÈëÎïÏà¹ØµÄALCLÊÇÒ»ÖÖ²î±ðÓÚÆäËûALK-ALCLµÄ¼²²¡ÀàÐÍÊÇÒ»ÖÖ·ÇÇÖÈëÐÔÖ×ÁöÓë´Ö²ÚÍâòÈé·¿Ö²ÈëÎïÏà¹ØÁÙ´²Ô¤ºóÏà¶Ô½ÏºÃµ«ÈôÊÇÇÖÕ¼Ïà½ü½á¹¹ÔòÔ¤ºó±ä²îÁÜͶºÏTÂËÅݸ¨Öú(TFH)ϸ°ûÁܰÍÁöNodal T-follicular helper(TFH) cell lymphomaÁÜͶºÏTFHϸ°ûÁܰÍÁöѪ¹ÜÃâÒßĸϸ°ûÐÍ?Nodal TFH cell lymphoma ,angioimmunoblastic-type£¨nTFHL-AI£©Ñª¹ÜÃâÒßĸϸ°ûÐÔTϸ°ûÁܰÍÁö£¨AITL£©ÁÜͶºÏTFHϸ°ûÁܰÍÁöÂËÅÝÐÍ?Nodal TFH cell lymphoma ,follicular-type£¨nTFHL-F£©ÂËÅÝÐÔTϸ°ûÁܰÍÁöÁÜͶºÏTFHϸ°ûÁܰÍÁö·ÇÌØÖ¸ÐÍ?Nodal TFH cell lymphoma ,NOS£¨nTFHL-NOS£©¾ßÓÐTFH±íÐ͵ĽáÐÔÍâÖÜTϸ°ûÁܰÍÁö¡¾×¢¡¿ÁÜͶºÏÂËÅݸ¨ÖúÐÔTϸ°ûÁܰÍÁö£¨nTFHL£©¼Ò×å°üÀ¨3¸ö¼²²¡ÊµÌå/ÀàÐ;ùϵÁÜͶºÏTϸ°ûÁܰÍÁö¾ßÓÐTFH£¨ÂËÅݸ¨ÖúÐÔTϸ°û£©µÄ±íÐͺͻùÒò±í´ïÌØÕ÷nTFHL-AIangioimmunoblastic-type ¶ÔÓ¦ÓÚÒÔǰµÄѪ¹ÜÃâÒßĸϸ°ûÐÔTϸ°ûÁܰÍÁönTFHL-Follicular-type ¹ØÓÚÓ¦ÓÚÒÔǰµÄÂËÅÝTϸ°ûÁܰÍÁönTFHL-NOS ¶ÔÓ¦ÓÚÒÔǰµÄ¾ßÓÐTFH±íÐ͵ÄÍâÖÜTϸ°ûÁܰÍÁöÆäËûÍâÖÜTϸ°ûÁܰÍÁöÍâÖÜTϸ°ûÁܰÍÁö·ÇÌØÖ¸ÐÍ£¨NOS£©?Peripheral T-cell lymphoma,not otherwise specified(NOS)Ïàͬ¡¾×¢¡¿PTCL-NOSÊÇÒ»×éÒìÖÊÐÔºÜÇ¿µÄ¼²²¡ÊÇɨ³ýÐÔÕï¶ÏÌØÊâÒªÅбðnTFHLEBVÑôÐÔNK/Tϸ°ûÁܰÍÁöEBV-positive NK/T-cell lymphomasEBVÑôÐÔ½áÐÔTϸ°ûºÍNKϸ°ûÁܰÍÁö?EBV-positive nodal T- and NK-cell lymphomaÎÞ½áÍâNK/Tϸ°ûÁܰÍÁö£¨ENKTL£©?Extranodal NK/T-cell lymphoma½áÍâNK/Tϸ°ûÁܰÍÁö±ÇÐÍ¡¾×¢¡¿½áÍâNK/Tϸ°ûÁܰÍÁö£¨ENKTL£©¿É±¬·¢ÔÚ²î±ðµÄ½áÍⲿλÒò´Ëɾ³ý¾É°æÖеÄÏÞÖÆ´Ê±ÇÐÍEBVÑôÐÔ½áÐÔTϸ°ûºÍNKϸ°ûÁܰÍÁö¼ÈÍù±»¹éÈëPTCL-NOSϵÄÒ»¸öÑÇÐÍÔÚаæ·ÖÀàÖÐ×÷Ϊһ¸ö×ÔÁ¦µÄ¼²²¡ÊµÌå/ÀàÐÍÖ÷Òª±¬·¢ÔÚ¶«ÑÇÈËÖÐÔ¤ºó²î¶ùͯEBVÑôÐÔTϸ°ûºÍNKϸ°ûÁܰÍÔöÖ³ºÍÁܰÍÁöEBV-positive T- and NK-cell lymphoid proliferations and lymphomas of childhoodÑÏÖØÎó涣ҧ¹ýÃô?Severe mosquito bite allergyÏàͬÖÖ¶»ÑùË®ð岡ÁܰÍÔöÖ³ÐÔ¼²²¡?Hydroa vacciniforme LPD(HVLPD)ÖÖ¶»ÑùË®ð岡Ñù£¨Hydroa vacciniforme-like£©ÁܰÍÔöÖ³ÐÔ¼²²¡ÏµÍ³ÐÔÂýÐÔÔ˶¯ÐÔEBV¼²²¡£¨ÏµÍ³ÐÔCAEBVD£©?Systemic chronic active EBV diseaseTϸ°ûºÍNKϸ°ûÀàÐ͵ÄÂýÐÔÔ˶¯ÐÔEBVѬȾϵͳÐÔ¶ùͯϵͳÐÔEBVÑôÐÔTϸ°ûÁܰÍÁö?Systemic EBV-positive T-cell lymphoma of childhoodÏàͬ¡¾×¢¡¿£¨1£©ÂýÐÔÔ˶¯ÐÔEBV²¡£¨CAEBVD£©£º°üÀ¨¾ÖÔîÖ¢×´ºÍ/»ò¶èÐÔÐÎʽµÄÑÏÖØÎó涣ҧ¹ýÃô?ºÍHVLPD¾­µä·¶?ÒÔ¼°È«ÉíÐÔ¼²²¡HVLPDÈ«ÉíÐÍ?ºÍϵͳÐÔCAEBVD?£¨2£©¶ùͯϵͳÐÔEBVÑôÐÔTϸ°ûÁܰÍÁö?Hydroa vacciniforme£¨ÖÖ¶»ÑùË®ð岡¶»´¯ÑùË®ð岡£©ÁܰÍ×éÖ¯µÄ¼äÖÊÔ´ÐÔÖ×ÁöStroma-derived neoplasms of lymphoid tissues£¨7¸öʵÌå/ÀàÐÍ£©µÚÎå°æ·ÖÀàµÚËİ棨ÐÞ¶©£©·ÖÀà¼äÖÊÊ÷ͻϸ°ûÖ×ÁöMesenchymal dendritic cell neoplasmsÂËÅÝÊ÷ͻϸ°ûÈâÁö?Follicualr dendritic cell sarcomaÏàͬEBV-ÑôÐÔÑ×ÐÔÂËÅÝÊ÷ͻϸ°ûÈâÁö?EBV-positive inflammatory follicular dendritic cell sarcomaÑ×ÐÔ¼ÙÁöÑùÂËÅÝ/³ÉÏËάϸ°ûÊ÷ͻϸ°ûÈâÁöÏËάĸϸ°ûÍø×´Ï¸°ûÁö?Fibroblastic reticular cell tumorÏàͬ¼¡ÏËάĸϸ°ûÁöMyofibroblastic tumour½áÄÚÕ¤À¸×´¼¡ÏËάĸϸ°ûÁö?Intranodal palisaded myofibroblastomaÎÞÆ¢ÌØÒìÐÔѪ¹Ü¼äÖÊÖ×ÁöSpleen-specific vascular-stromal tumoursƢѪ¹Ü¼äÖÊÁöSplenic vascular-stromal tumoursÆ¢ñ¼°¶Ï¸°ûѪ¹ÜÁö?Littoral cell angiomaÎÞÆ¢´í¹¹Áö?Splenic hamartomaÎÞÆ¢Ó²»¯ÐÔѪ¹ÜÁöÑù½á½ÚÐÔת»¯?Sclerosing angiomatoid nodular transformation of spleenÎÞ¡¾×¢¡¿1¡¢ÁܰÍ×éÖ¯¼äÖÊÔ´ÐÔÖ×ÁöµÄijЩÀàÐÍÊÇÁÜͶºÏ»òÆ¢ÔàËùÌØÓеĹéÈëÌìÖ°ÀàϵͳÖзÇÁÜͶºÏºÍÆ¢ÔàÌØÒìÐÔµÄÈí×éÖ¯Ö×Áö£¨ºÃ±ÈѪ¹ÜÁö¡¢Ñª¹ÜÈâÁö¡¢Áܰ͹ܼ¡Áö¡¢¿¨²¨Î÷ÈâÁöµÈ£©¹éµ½2020ÄêµÚÎå°æWHO¹ÇºÍÈí×éÖ¯Ö×Áö·ÖÀàÖÐ2¡¢ÁܰÍ×éÖ¯¼äÖÊ£¨»ùÖÊ£©ÈªÔ´Ö×ÁöÊǵÚÎå°æÐÂÒýÈëµÄ·ÖÀà¸ÃÖÖ±ðϰüÀ¨Èý´óÀࣺ£¨1£©¼äÖÊÊ÷ͻϸ°ûÖ×Áö£º´Ó×é֯ϸ°ûºÍÊ÷ͻϸ°ûÖ×ÁöÖÖ±ðÖÐÒÆ¹ýÀ´µÄÂËÅÝÊ÷ͻϸ°ûÖ×Áö£¨?ºÍ?£©ºÍ³ÉÏËÎ¬Íø×´Ï¸°ûÖ×Áö?¹éÈëÕâÒ»ÐÂÖÖÓÖÃûÏ£¨ÓÉÓÚÂËÅÝÊ÷ͻϸ°û²¢·ÇÔ´×ÔÔìѪ¸Éϸ°û¶øÊǼäÖÊȪԴ£©ÁíÍâEBVÑôÐÔÑ×ÐÔÂËÅÝÊ÷ͻϸ°ûÈâÁö?ÓÉÓÚ¾ßÓÐÆæÒìµÄÁÙ´²²¡ÀíÌØÕ÷´ÓÂËÅÝÊ÷ͻϸ°ûÈâÁö?Öе¥ÁгöÀ´×÷Ϊ×ÔÁ¦µÄ¼²²¡ÀàÐÍ£¨2£©¼¡ÏËάĸϸ°ûÁöϵÁÜͶºÏÌØÒìÐÔ¼äÖÊÖ×Áö£¨ÁÜͶºÏÄÚÕ¤À¸×´¼¡ÏËάĸϸ°ûÁö?£©£¨3£©Æ¢ÌØÒìÐÔ¼äÖÊÖ×Áö°üÀ¨£ºÆ¢ñ¼°¶Ï¸°ûѪ¹ÜÁö?¡¢Æ¢´í¹¹Áö?¡¢Æ¢Ó²»¯ÐÔѪ¹ÜÁöÑù½á½ÚÐÔת»¯?£©Ê÷ͻϸ°ûºÍ×é֯ϸ°ûÖ×ÁöDendritic cell and histiocytic neoplasms£¨11¸öʵÌå/ÀàÐÍ£©µÚÎå°æµÚËİ棨ÐÞ¶©£©·ÖÀཬϸ°ûÑùÊ÷ͻϸ°ûÖ×ÁöPlasmacytoid dendritic cell neoplasmsÓëËèϵÖ×ÁöÏà¹ØµÄ³ÉÊ콬ϸ°ûÑùÊ÷ͻϸ°ûÔöÖ³Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasmÎÞĸϸ°ûÐÔ½¬Ï¸°ûÑùÊ÷ͻϸ°ûÖ×ÁöBlastic plasmacytoid dendritic cell neoplasmÎÞÀɸñººË¹Ï¸°ûºÍÆäËûÊ÷ͻϸ°ûÖ×ÁöLangerhans cell and other dendritic cell neoplasmsÀɸñººË¹Ï¸°ûÖ×ÁöLangerhans cells neoplasmsÀɸñººË¹Ï¸°û×é֯ϸ°ûÔöÉúÖ¢Langerhans cell histiocytosisÏàͬÀɸñººË¹Ï¸°ûÈâÁöLangerhans cell sarcomaÏàͬÆäËûÊ÷ͻϸ°ûÖ×ÁöOther dendritic cell neoplasms䶨ÀàÊ÷ͻϸ°ûÁöIndeterminate dendritic cell tumourÏàͬ£¨Î´È·¶¨Ê÷ͻϸ°ûÖ×Áö£©Ö¸Í»×´Ê÷ͻϸ°ûÈâÁöInterdigitating dendritic cell sarcomaÏàͬ£¨½»Ö¸Ê÷ͻϸ°ûÈâÁö£©×é֯ϸ°ûÖ×ÁöHistiocytic neoplasmsÓ×Äê»ÆÉ«ÈâÑ¿Ö×Juvenile xanthogranulomaÏàͬ£¨²¥É¢ÐÔÓ×Äê»ÆÉ«ÈâÑ¿Ö×£©Erdheim-Chester²¡£¨ECD£©Erdheim-Chester diseaseÏàͬRosai-Dorfman²¡£¨RDD£©Rosai-Dorfman diseaseÎÞALKÑôÐÔ×é֯ϸ°ûÔöÉúÖ¢ALK-positive histiocytosisÎÞ×é֯ϸ°ûÈâÁöHistiocytic sarcomaÏàͬ¡¾×¢¡¿×é֯ϸ°û/Ê÷ͻϸ°ûÖ×ÁöÔÚаæ·ÖÀàϵͳÖж¨Î»ÓÚËèϵÖ×ÁöÖ®ºóͨ³£ÒÔΪËüÃÇÆðÔ´ÓÚ³£¼ûµÄËèÏµ×æÏ¸°û£¨ËèÏµ×æÏ¸°û±¬·¢µ¥ºËϸ°û/×é֯ϸ°û/Ê÷ͻϸ°ûÆ×ϵ£©µÚËİæ×é֯ϸ°û/Ê÷ͻϸ°ûÖ×ÁöϵÄÂËÅÝÊ÷ͻϸ°ûÈâÁö¡¢³ÉÏËά£¨ÏËάĸϸ°û£©Íø×´Ï¸°ûÖ×Áö˼Á¿µ½ÊÇÓÉÁܰͻùÖÊϸ°û±¬·¢µÄÖ×ÁöµÚÎå°æ·ÖÀཫÆä´Ó×é֯ϸ°û/Ê÷ͻϸ°ûÖ×ÁöÖзֳöÀ´¹éÈëµ½ÁÜϵÖ×ÁöÁܰÍ×éÖ¯¼äÖÊÔ´ÐÔÖ×Áöϲο¼ÎÄÏ×£º£¨1£©The 5th edition of the World Health Organization Classifification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia(2022) 36:1703-1719.https://doi.org/10.1038/s41375-022-01613-1.£¨2£©The 5th edition of the World Health Organization Classifification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia(2022) 36:1720-1748.https://doi.org/10.1038/s41375-022-01620-2.

ÕÔÁ¯ÔÆÏÖÔÚ¹òÔÚËýµÄÑÛǰ×ÅʵÒѾ­»èØÊ¶àÈÕËý¾ø¶Ô²»»áÖªµÀÎ§ÈÆ×ÅËýΪÖÐÐÄÕû¸öÊ®´ó¹ÅÅÉ¹ÎÆðÁËÒ»³¡ºÎµÈÐÚÓ¿ØÏ²âµÄ°µ³±·ç±©447·ÖÇáÇáËÉËɾÍÄÜ¿¼ÉÏÌÃÌÃÖйúÈËÃñ¹«°²´óѧÕâÊÂÒ»³ö²»ÉÙ¿¼ÉúºÍ¼Ò³¤¶¼Õð¾ªÁË

Ëø¶¨ÖصãÈËȺÑŰ²Î§ÈÆÖ°ÒµÈËȺ¡¢ÀÏÈË¡¢¶ùͯÇàÉÙÄêµÈÍÆ¶¯²âÌåÖØ¡¢ËãÖ¸Êý¡¢Á¿ÑüΧÔ˶¯×ß½øÑ§Ð£¡¢ÖÝÀï¡¢ÉçÇø¡¢µ¥Î»µÈºÃ±ÈÈ¥Äê12ÔÂÑŰ²ÊÐÎÀÉú¿µ½¡Î¯ÔÚÑŰ²ÊÐÐÐÕþÖÐÐÄ×éÖ¯¿ªÕ¹¿µ½¡ÌåÖØ Ò»ÆðÐж¯½ø»ú¹ØÖ÷ÌâÔ˶¯ÒÔÓÎÔ°´ðÌ⡢֪ʶ¾º²Â¡¢¼õÖØÐ¡¿ÎÌõÈÐÎʽÎüÒý600ÓàÈ˼ÓÈëÓÎÔ°Ô˶¯

µ¼ÑÝ£º
¸üУº

2025-09-20 16:04:20

±¸×¢£º
¹úÓï
ÆÀ¼Û£º
½ÒÃØÄÉÎ÷æ§Âú¼¶½Å·¨µÄÎå´ó½¹µã¼¼ÇÉ ÄÉÎ÷æ§Âú¼¶½Å·¨...
Ê×Ò³
Ó°Ï·
Ò»Á¬¾ç
×ÛÒÕ
¶¯Âþ
APP
ÍøÕ¾µØÍ¼